GSK slides after buying cancer firm Tesaro for hefty $5.1 billion

GSK has lagged rivals in recent years in producing multibillion-dollar blockbusters and it largely sat out a spate of dealmaking by rival drugmakers under previous CEO Andrew Witty. That is a situation Walmsley wants to change.

Original source:

Related Posts